NCT03024034View on ClinicalTrials.gov

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

December 1, 2017

Study Completion Date

June 4, 2018

Conditions
Bacterial Infections
Interventions
DRUG

TP-271

single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT03024034 - A Phase 1 TP-271 Oral PK Single Ascending Dose Study | Biotech Hunter | Biotech Hunter